A trial team from Wilson Sonsini Goodrich & Rosati delivered a $1 billion save for client Amphastar Pharmaceuticals Inc. after a federal jury in Boston on Friday sided with the company in a patent fight over its generic version of the blood-thinner Lovenox.
Wilson Sonsini partners Michael Sommer and Doug Carsten led Amphastar’s team, squaring off against Momenta Pharmaceuticals Inc., represented by Choate, Hall & Stewart, and Novartis AG’s Sandoz unit, represented by Morrison & Foerster.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
